


Bacitracin vials



Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.

Indication: The use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug.

Application: Administered systemically as intramuscular injections.

| Dosage form | Lyophilized vials |
|--------------------------|--|
| Strength | 50000 units/vial |
| Compliance | USP |
| Manufacturing site | CMO for Xellia Pharmaceuticals ApS |
| Release site | CMO for Xellia Pharmaceuticals ApS |
| Site registered | EU GMP issued by Medicines and Healthcare products Regulatory Agency US FDA Other health authorities |
| Regulatory documentation | US dossier |
| Batch size | 35000 vials 17000 vials |
| Packaging sizes | 1 vial/pack 10 vials/pack |
| Shelf-life | 24 months |
| Storage conditions | Between 2-8°C (36-46°F) |